{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:22:30Z","timestamp":1785936150782,"version":"3.56.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Cancer Institute","award":["R01CA194742"],"award-info":[{"award-number":["R01CA194742"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01645-3","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:02:52Z","timestamp":1737331372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects"],"prefix":"10.1186","volume":"18","author":[{"given":"Ada Alice","family":"Dona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theophilus","family":"Tandoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Nigam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Caserta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Murtadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Moloudizargari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Winchester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Pozhitkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawa","family":"Vahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Nuovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Pichiorri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C","family":"Hofmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"1645_CR1","unstructured":"Berkrot B. FDA Approves Amgen\u2019s Injected Immunotherapy for Melanoma 2015 http:\/\/www.reuters.com\/article\/2015\/10\/27\/us-amgen-fda-idUSKCN0SL2YH20151027"},{"issue":"7","key":"1645_CR2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1517\/14712590903002039","volume":"9","author":"K Kelly","year":"2009","unstructured":"Kelly K, Nawrocki S, Mita A, Coffey M, Giles FJ, Mita M. Reovirus-based therapy for cancer. Expert Opin Biol Ther. 2009;9(7):817\u201330.","journal-title":"Expert Opin Biol Ther"},{"issue":"3386","key":"1645_CR3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.130.3386.1387","volume":"130","author":"AB Sabin","year":"1959","unstructured":"Sabin AB, Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Science. 1959;130(3386):1387\u20139.","journal-title":"Science"},{"issue":"6333","key":"1645_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.aah5298","volume":"356","author":"R Bouziat","year":"2017","unstructured":"Bouziat R, Hinterleitner R, Brown JJ, Stencel-Baerenwald JE, Ikizler M, Mayassi T, et al. Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science. 2017;356(6333):44\u201350.","journal-title":"Science"},{"issue":"3","key":"1645_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4161\/auto.22867","volume":"9","author":"CM Thirukkumaran","year":"2013","unstructured":"Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N, et al. Reovirus modulates autophagy during oncolysis of multiple myeloma. Autophagy. 2013;9(3):413\u20134.","journal-title":"Autophagy"},{"issue":"2","key":"1645_CR6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1128\/jvi.28.2.444-449.1978","volume":"28","author":"MR Duncan","year":"1978","unstructured":"Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol. 1978;28(2):444\u20139.","journal-title":"J Virol"},{"issue":"4","key":"1645_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/BF01314776","volume":"54","author":"G Hashiro","year":"1977","unstructured":"Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol. 1977;54(4):307\u201315.","journal-title":"Arch Virol"},{"issue":"3","key":"1645_CR8","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1074\/jbc.M004680200","volume":"276","author":"ES Barton","year":"2001","unstructured":"Barton ES, Connolly JL, Forrest JC, Chappell JD, Dermody TS. Utilization of sialic acid as a coreceptor enhances reovirus attachment by multistep adhesion strengthening. J Biol Chem. 2001;276(3):2200\u201311.","journal-title":"J Biol Chem"},{"issue":"3","key":"1645_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0092-8674(01)00231-8","volume":"104","author":"ES Barton","year":"2001","unstructured":"Barton ES, Forrest JC, Connolly JL, Chappell JD, Liu Y, Schnell FJ, et al. Junction adhesion molecule is a receptor for reovirus. Cell. 2001;104(3):441\u201351.","journal-title":"Cell"},{"issue":"2","key":"1645_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1128\/jvi.56.2.356-364.1985","volume":"56","author":"JR Gentsch","year":"1985","unstructured":"Gentsch JR, Pacitti AF. Effect of neuraminidase treatment of cells and effect of soluble glycoproteins on type 3 reovirus attachment to murine L cells. J Virol. 1985;56(2):356\u201364.","journal-title":"J Virol"},{"issue":"38","key":"1645_CR11","doi-asserted-by":"publisher","first-page":"41275","DOI":"10.18632\/oncotarget.5753","volume":"6","author":"KR Kelly","year":"2015","unstructured":"Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, et al. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget. 2015;6(38):41275\u201389.","journal-title":"Oncotarget"},{"issue":"5","key":"1645_CR12","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1158\/1535-7163.MCT-15-0240-T","volume":"15","author":"A Stiff","year":"2016","unstructured":"Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, et al. Histone deacetylase inhibitors enhance the therapeutic potential of Reovirus in multiple myeloma. Mol Cancer Ther. 2016;15(5):830\u201341.","journal-title":"Mol Cancer Ther"},{"issue":"5392","key":"1645_CR13","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","volume":"282","author":"MC Coffey","year":"1998","unstructured":"Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science. 1998;282(5392):1332\u20134.","journal-title":"Science"},{"issue":"12","key":"1645_CR14","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","volume":"17","author":"JE Strong","year":"1998","unstructured":"Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the ras signaling pathway by reovirus. EMBO J. 1998;17(12):3351\u201362.","journal-title":"EMBO J"},{"key":"1645_CR15","doi-asserted-by":"crossref","unstructured":"Kelly K, Espitia CM, Medina EC, Mahalingham D, Oyajobi BO, Coffey M, Giles FJ, Carew JS, Nawrocki S. Reolysin induces endoplasmic reticular stress in multiple myeloma and enhances the activity of bortezomib. Eur J Cancer Suppl. 2010;8(7):183.","DOI":"10.1016\/S1359-6349(10)72287-4"},{"issue":"18","key":"1645_CR16","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1158\/1078-0432.CCR-11-3085","volume":"18","author":"CM Thirukkumaran","year":"2012","unstructured":"Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N, et al. Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin cancer Research: Official J Am Association Cancer Res. 2012;18(18):4962\u201372.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"23","key":"1645_CR17","doi-asserted-by":"publisher","first-page":"5946","DOI":"10.1158\/1078-0432.CCR-14-1404","volume":"20","author":"DW Sborov","year":"2014","unstructured":"Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr., et al. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin cancer Research: Official J Am Association Cancer Res. 2014;20(23):5946\u201355.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"key":"1645_CR18","doi-asserted-by":"crossref","unstructured":"M\u00fcller LME, Migneco G, Scott GB, Down J, King S, Askar B et al. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. J Immunother Cancer. 2021;9(3).","DOI":"10.1136\/jitc-2020-001803"},{"issue":"10272","key":"1645_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"5","key":"1645_CR20","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","volume":"114","author":"T Hideshima","year":"2009","unstructured":"Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, et al. Bortezomib induces canonical nuclear factor-kappab activation in multiple myeloma cells. Blood. 2009;114(5):1046\u201352.","journal-title":"Blood"},{"issue":"25","key":"1645_CR21","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1038\/onc.2011.478","volume":"31","author":"KR Kelly","year":"2012","unstructured":"Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, et al. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene. 2012;31(25):3023\u201338.","journal-title":"Oncogene"},{"issue":"24","key":"1645_CR22","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1158\/1078-0432.CCR-23-0229","volume":"29","author":"ST Nawrocki","year":"2023","unstructured":"Nawrocki ST, Olea J, Villa Celi C, Dadrastoussi H, Wu K, Tsao-Wei D, et al. Comprehensive single-cell immune profiling defines the patient multiple myeloma microenvironment following oncolytic virus therapy in a phase ib trial. Clin cancer Research: Official J Am Association Cancer Res. 2023;29(24):5087\u2013103.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"5","key":"1645_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1182\/bloodadvances.2018025593","volume":"3","author":"CM Thirukkumaran","year":"2019","unstructured":"Thirukkumaran CM, Shi ZQ, Nuovo GJ, Luider J, Kopciuk KA, Dong Y, et al. Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. Blood Adv. 2019;3(5):797\u2013812.","journal-title":"Blood Adv"},{"issue":"19","key":"1645_CR24","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","volume":"114","author":"HS Robins","year":"2009","unstructured":"Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009;114(19):4099\u2013107.","journal-title":"Blood"},{"key":"1645_CR25","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1038\/ncomms3680","volume":"4","author":"CS Carlson","year":"2013","unstructured":"Carlson CS, Emerson RO, Sherwood AM, Desmarais C, Chung MW, Parsons JM, et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun. 2013;4:2680.","journal-title":"Nat Commun"},{"issue":"1\u20132","key":"1645_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jim.2011.09.001","volume":"375","author":"H Robins","year":"2012","unstructured":"Robins H, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H, et al. Ultra-sensitive detection of rare T cell clones. J Immunol Methods. 2012;375(1\u20132):14\u20139.","journal-title":"J Immunol Methods"},{"issue":"4","key":"1645_CR27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41579-020-00449-9","volume":"19","author":"JE Jones","year":"2021","unstructured":"Jones JE, Le Sage V, Lakdawala SS. Viral and host heterogeneity and their effects on the viral life cycle. Nat Rev Microbiol. 2021;19(4):272\u201382.","journal-title":"Nat Rev Microbiol"},{"issue":"138","key":"1645_CR28","doi-asserted-by":"publisher","first-page":"138ra77","DOI":"10.1126\/scitranslmed.3003578","volume":"4","author":"RA Adair","year":"2012","unstructured":"Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med. 2012;4(138):138ra77.","journal-title":"Sci Transl Med"},{"key":"1645_CR29","doi-asserted-by":"crossref","unstructured":"Zamora PF, Hu L, Knowlton JJ, Lahr RM, Moreno RA, Berman AJ et al. Reovirus nonstructural protein \u03c3NS acts as an RNA stability factor promoting viral genome replication. J Virol. 2018;92(15).","DOI":"10.1128\/JVI.00563-18"},{"issue":"3","key":"1645_CR30","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ccell.2020.12.022","volume":"39","author":"E Ramelyte","year":"2021","unstructured":"Ramelyte E, Tastanova A, Bal\u00e1zs Z, Ignatova D, Turko P, Menzel U, et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Cancer Cell. 2021;39(3):394\u2013e4064.","journal-title":"Cancer Cell"},{"issue":"20","key":"1645_CR31","doi-asserted-by":"publisher","first-page":"18092","DOI":"10.1074\/jbc.M300265200","volume":"278","author":"P Clarke","year":"2003","unstructured":"Clarke P, Meintzer SM, Moffitt LA, Tyler KL. Two distinct phases of virus-induced nuclear factor kappa B regulation enhance tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected cells. J Biol Chem. 2003;278(20):18092\u2013100.","journal-title":"J Biol Chem"},{"issue":"3","key":"1645_CR32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1089\/vim.2006.19.546","volume":"19","author":"AL Farone","year":"2006","unstructured":"Farone AL, O\u2019Donnell SM, Brooks CS, Young KM, Pierce JM, Wetzel JD, et al. Reovirus strain-dependent inflammatory cytokine responses and replication patterns in a human monocyte cell line. Viral Immunol. 2006;19(3):546\u201357.","journal-title":"Viral Immunol"},{"issue":"18","key":"1645_CR33","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691\u20135.","journal-title":"Blood"},{"issue":"1","key":"1645_CR34","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s13046-022-02566-0","volume":"41","author":"N Porciello","year":"2022","unstructured":"Porciello N, Franzese O, D\u2019Ambrosio L, Palermo B, Nistic\u00f2 P. T-cell repertoire diversity: friend or foe for protective antitumor response? J Experimental Clin cancer Research: CR. 2022;41(1):356.","journal-title":"J Experimental Clin cancer Research: CR"},{"issue":"3","key":"1645_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1189\/jlb.0806507","volume":"81","author":"J Ennaciri","year":"2007","unstructured":"Ennaciri J, Ahmad R, Menezes J. Interaction of monocytic cells with respiratory syncytial virus results in activation of NF-kappaB and PKC-alpha\/beta leading to up-regulation of IL-15 gene expression. J Leukoc Biol. 2007;81(3):625\u201331.","journal-title":"J Leukoc Biol"},{"key":"1645_CR36","doi-asserted-by":"publisher","first-page":"598444","DOI":"10.3389\/fimmu.2020.598444","volume":"11","author":"R Kircheis","year":"2020","unstructured":"Kircheis R, Haasbach E, Lueftenegger D, Heyken WT, Ocker M, Planz O. NF-\u03baB pathway as a potential target for treatment of critical stage COVID-19 patients. Front Immunol. 2020;11:598444.","journal-title":"Front Immunol"},{"issue":"17","key":"1645_CR37","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","volume":"115","author":"YN Demchenko","year":"2010","unstructured":"Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and\/or alternative NF-kappaB pathway activation in multiple myeloma. Blood. 2010;115(17):3541\u201352.","journal-title":"Blood"},{"key":"1645_CR38","doi-asserted-by":"crossref","unstructured":"Khalife J, Ghose J, Martella M, Viola D, Rocci A, Troadec E et al. MiR-16 regulates crosstalk in NF-\u03baB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. JCI Insight. 2019;4(21).","DOI":"10.1172\/jci.insight.129348"},{"issue":"8","key":"1645_CR39","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754\u201366.","journal-title":"N Engl J Med"},{"issue":"29","key":"1645_CR40","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","volume":"26","author":"A Chanan-Khan","year":"2008","unstructured":"Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26(29):4784\u201390.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1645_CR41","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1182\/blood.2023022777","volume":"143","author":"A Gulla","year":"2024","unstructured":"Gulla A, Morelli E, Johnstone M, Turi M, Samur MK, Botta C, et al. Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma. Blood. 2024;143(25):2612\u201326.","journal-title":"Blood"},{"issue":"1","key":"1645_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","volume":"15","author":"F Seif","year":"2017","unstructured":"Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Communication Signaling: CCS. 2017;15(1):23.","journal-title":"Cell Communication Signaling: CCS"},{"issue":"4","key":"1645_CR43","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41590-019-0350-0","volume":"20","author":"JP Twohig","year":"2019","unstructured":"Twohig JP, Cardus Figueras A, Andrews R, Wiede F, Cossins BC, Derrac Soria A, et al. Activation of na\u00efve CD4(+) T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4(+) T cells. Nat Immunol. 2019;20(4):458\u201370.","journal-title":"Nat Immunol"},{"issue":"5","key":"1645_CR44","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","volume":"2","author":"A Gulla","year":"2021","unstructured":"Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, et al. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation. Blood cancer Discovery. 2021;2(5):468\u201383.","journal-title":"Blood cancer Discovery"},{"issue":"9","key":"1645_CR45","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1158\/1078-0432.CCR-10-3266","volume":"17","author":"EJ Ilett","year":"2011","unstructured":"Ilett EJ, Barcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, et al. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin cancer Research: Official J Am Association Cancer Res. 2011;17(9):2767\u201376.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"5","key":"1645_CR46","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/gt.2009.29","volume":"16","author":"EJ Ilett","year":"2009","unstructured":"Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther. 2009;16(5):689\u201399.","journal-title":"Gene Ther"},{"issue":"10","key":"1645_CR47","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/2326-6066.CIR-18-0309","volume":"6","author":"RA Berkeley","year":"2018","unstructured":"Berkeley RA, Steele LP, Mulder AA, van den Wollenberg DJM, Kottke TJ, Thompson J, et al. Antibody-neutralized reovirus is effective in oncolytic virotherapy. Cancer Immunol Res. 2018;6(10):1161\u201373.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"1645_CR48","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/mt.2014.118","volume":"22","author":"E Ilett","year":"2014","unstructured":"Ilett E, Kottke T, Donnelly O, Thompson J, Willmon C, Diaz R, et al. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. Mol Therapy: J Am Soc Gene Therapy. 2014;22(10):1851\u201363.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"issue":"3","key":"1645_CR49","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3324\/haematol.2017.176859","volume":"103","author":"J Koreth","year":"2018","unstructured":"Koreth J, Kim HT, Lange PB, Poryanda SJ, Reynolds CG, Rai SC, et al. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. 2018;103(3):522\u201330.","journal-title":"Haematologica"},{"issue":"1","key":"1645_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13045-020-00919-w","volume":"13","author":"V Marchica","year":"2020","unstructured":"Marchica V, Franceschi V, Vescovini R, Storti P, Vicario E, Toscani D, et al. Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy. J Hematol Oncol. 2020;13(1):89.","journal-title":"J Hematol Oncol"},{"issue":"21","key":"1645_CR51","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1158\/1078-0432.CCR-16-1003","volume":"22","author":"JY Yoo","year":"2016","unstructured":"Yoo JY, Jaime-Ramirez AC, Bolyard C, Dai H, Nallanagulagari T, Wojton J, et al. Bortezomib treatment sensitizes oncolytic HSV-1-treated tumors to NK cell immunotherapy. Clin cancer Research: Official J Am Association Cancer Res. 2016;22(21):5265\u201376.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"1","key":"1645_CR52","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/leu.2017.272","volume":"32","author":"KR Kelly","year":"2018","unstructured":"Kelly KR, Espitia CM, Zhao W, Wu K, Visconte V, Anwer F, et al. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia. 2018;32(1):230\u20133.","journal-title":"Leukemia"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01645-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01645-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01645-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:02:57Z","timestamp":1737331377000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01645-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1645"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01645-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ohio State University Cancer Institutional Review Board (Columbus, OH) approved this study, and informed consent was obtained from all enrolled patients (, NCT 02101944). All animal experiments were approved by the City of Hope Institutional Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GJN received research funding from Oncolytics Biotech Inc. MC is employed by Oncolytics Biotech Inc. CCH received research funding from BMS, Oncolytics Biotech, Sanofi, and Nektar; he received personal funds from GlaxoSmithKline, Oncopeptides, BMS, Janssen, Sanofi, and Celgene for advisory board participation, and patent-related funds from Recursion Pharmaceuticals. DWS received personal funds for consultation and advisory board participation from Sanofi, Janssen, SkylineDx, GlaxoSmithKline, Legend Biotech and Amgen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}